

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (FG-149)

LIFIRAFENIB

PRONUNCIATION

li fir ra fen' ib


THERAPEUTIC CLAIM

Antineoplastic

CHEMICAL NAMES

- 1,8-Naphthyridin-2(1*H*)-one, 5-[[[(1*R*,1*aS*,6*bR*)-1*a*,6*b*-dihydro-1-[6-(trifluoromethyl)-1*H*-benzimidazol-2-yl]-1*H*-cyclopropano[*b*]benzofuran-5-yl]oxy]-3,4-dihydro-
- 5-[[[(1*R*,1*aS*,6*bR*)-1-[5-(trifluoromethyl)-1*H*-benzimidazol-2-yl]-1*a*,6*b*-dihydro-1*H*-cyclopropano[*b*][1]benzofuran-5-yl]oxy]-3,4-dihydro-1,8-naphthyridin-2(1*H*)-one

STRUCTURAL FORMULA



MOLECULAR FORMULA

C₂₅H₁₇F₃N₄O₃

MOLECULAR WEIGHT

478.4

TRADEMARK

None as yet

SPONSOR

BeiGene USA, Inc.

CODE DESIGNATION

BGB-283

CAS REGISTRY NUMBER

1446090-79-4

UNII

8762XZS5ZF

WHO NUMBER

10554

SCS